Published in Int J Nanomedicine on July 05, 2017
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2006) 2.12
Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull (2002) 2.02
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res (2005) 1.84
Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci (1998) 1.77
Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res (2010) 1.33
Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol (2006) 1.22
Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol (2012) 1.21
Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea (2008) 1.15
Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res (2000) 1.15
Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res (2008) 1.11
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res (2013) 1.06
Subconjunctival bevacizumab for corneal neovascularization. Cornea (2008) 1.02
Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea (2009) 1.00
Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea (2008) 0.94
Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci (2008) 0.91
Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea (2008) 0.91
Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res (2001) 0.85
Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization. Ophthalmic Res (2011) 0.84
Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea (2008) 0.83
Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization. Int J Ophthalmol (2014) 0.80
Beneficial effects of the Src inhibitor, dasatinib, on breakdown of the blood-retinal barrier. Arch Pharm Res (2016) 0.78
Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage. Int J Nanomedicine (2016) 0.77
Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage. Int J Nanomedicine (2016) 0.77